Adaptimmune Therapeutics PLC (NASDAQ:ADAP)’s share price reached a new 52-week high on Friday . The stock traded as high as $8.52 and last traded at $8.60, with a volume of 1,100,507 shares trading hands. The stock had previously closed at $7.55.

A number of brokerages recently issued reports on ADAP. BidaskClub raised Adaptimmune Therapeutics PLC from a “sell” rating to a “hold” rating in a research report on Sunday, July 16th. Cowen and Company reissued a “buy” rating on shares of Adaptimmune Therapeutics PLC in a research report on Tuesday, June 6th. ValuEngine raised Adaptimmune Therapeutics PLC from a “strong sell” rating to a “sell” rating in a research report on Thursday, July 20th. Finally, Zacks Investment Research lowered Adaptimmune Therapeutics PLC from a “buy” rating to a “hold” rating in a research report on Monday, July 17th. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $12.08.

The stock’s market cap is $812.68 million. The stock’s 50 day moving average price is $5.62 and its 200 day moving average price is $5.16.

Adaptimmune Therapeutics PLC (NASDAQ:ADAP) last announced its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.24). The business had revenue of $3.52 million for the quarter, compared to analyst estimates of $5.43 million. Adaptimmune Therapeutics PLC had a negative return on equity of 38.73% and a negative net margin of 438.00%. On average, equities research analysts expect that Adaptimmune Therapeutics PLC will post ($0.99) earnings per share for the current year.

A number of large investors have recently made changes to their positions in ADAP. Matrix Capital Management Company LP bought a new position in Adaptimmune Therapeutics PLC in the second quarter worth approximately $39,027,000. NEA Management Company LLC boosted its holdings in Adaptimmune Therapeutics PLC by 21.7% in the first quarter. NEA Management Company LLC now owns 12,025,999 shares of the biotechnology company’s stock worth $66,263,000 after acquiring an additional 2,145,000 shares in the last quarter. AXA bought a new position in Adaptimmune Therapeutics PLC in the first quarter worth approximately $4,959,000. Tekla Capital Management LLC boosted its holdings in Adaptimmune Therapeutics PLC by 158.9% in the first quarter. Tekla Capital Management LLC now owns 1,466,368 shares of the biotechnology company’s stock worth $8,080,000 after acquiring an additional 900,000 shares in the last quarter. Finally, Point72 Asset Management L.P. bought a new position in Adaptimmune Therapeutics PLC in the first quarter worth approximately $2,883,000. Institutional investors and hedge funds own 68.01% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Adaptimmune Therapeutics PLC (ADAP) Sets New 1-Year High at $8.52” was posted by Daily Political and is owned by of Daily Political. If you are reading this article on another website, it was illegally copied and republished in violation of international trademark and copyright laws. The original version of this article can be read at https://www.dailypolitical.com/2017/09/08/adaptimmune-therapeutics-plc-adap-sets-new-1-year-high-at-8-52.html.

About Adaptimmune Therapeutics PLC

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients.